MEDICAL EXECUTIVE-POST – TODAY’S NEWSLETTER BRIEFING
***
Essays, Opinions and Curated News in Health Economics, Investing, Business, Management and Financial Planning for Physician Entrepreneurs and their Savvy Advisors and Consultants
“Serving Almost One Million Doctors, Financial Advisors and Medical Management Consultants Daily“
A Partner of the Institute of Medical Business Advisors , Inc.
http://www.MedicalBusinessAdvisors.com
SPONSORED BY: Marcinko & Associates, Inc.
***
http://www.MarcinkoAssociates.com
| Daily Update Provided By Staff Reporters Since 2007. How May We Serve You? |
| © Copyright Institute of Medical Business Advisors, Inc. All rights reserved. 2025 |
REFER A COLLEAGUE: MarcinkoAdvisors@outlook.com
SPONSORSHIPS AVAILABLE: https://medicalexecutivepost.com/sponsors/
ADVERTISE ON THE ME-P: https://tinyurl.com/ytb5955z
Your Referral Count -0-
Federal health agencies are canceled—well, their meetings are at least. In the days following his inauguration, President Donald Trump’s administration asked officials within the Department of Health and Human Services (HHS)—which has a $1.7 trillion budget and includes the FDA, the CDC, and the National Institutes of Health (NIH)—to stop all external communication, according to an internal memo. This means no new health advisories, social media posts, or website posts.
“As the new administration considers its plan for managing the federal policy and public communications processes, it is important that the president’s appointees and designees have the opportunity to review and approve any regulations, guidance documents, and other public documents and communications (including social media),” the memo read. The pause began on Jan. 21st, and according to the memo, will remain in effect until Feb. 1st
CITE: https://www.r2library.com/Resource
The FTC’s second interim staff report on consolidated pharmacy benefit managers (PBMs) found that the three largest of these middlemen—CVS Health’s Caremark Rx, Cigna Group’s Express Scripts, and UnitedHealth Group’s OptumRx—”marked up two specialty generic cancer drugs by thousands of percent and then paid their affiliated pharmacies hundreds of millions of dollars of dispensing revenue in excess of estimated acquisition costs for each drug annually.”
CITE: https://tinyurl.com/2h47urt5
The NASDAQ tanked on Monday as a Chinese startup rattled faith in US leadership and profitability in AI, taking a hammer to Nvidia (NVDA), wiping out a record $589 billion in market value. The NASDAQ Composite (^IXIC) sank more than 3%, while the S&P 500 (^GSPC) dropped nearly 1.5%. The blue-chip Dow Jones Industrial Average (^DJI), which is less dependent tech stocks gained more than 0.6% as investors flocked to defensive sectors. Shares of Apple (AAPL) and software giant Salesforce (CRM) also bucked the tech rout.
CITE: https://tinyurl.com/tj8smmes
Visualize: How private equity tangled banks in a web of debt, from the Financial Times.
COMMENTS APPRECIATED
PLEASE SUBSCRIBE: MarcinkoAdvisors@outlook.com
Thank You
***
***
***
***
EDUCATIONAL TEXTBOOKS: https://tinyurl.com/4zdxuuwf
***
Filed under: Drugs and Pharma, Ethics, Information Technology, Investing, Marcinko Associates, Recommended Books, Sponsors | Tagged: Apple, CDC, Cigna, CRM, CVs, CVS Health, DJIA, DOW, FTC, HHS, Marcinko, NASA, NASDAQ, NIH, OptumRx, PBMs, S&P 500, stocks plunge, technology stocks, textbooks, TNX, UnitedHealth, VIX, WSJ | Leave a comment »
















